

Does Bone Morphogenetic Protein Use Reduce Pseudarthrosis Rates in Single-Level Transforaminal Lumbar Interbody Fusion Surgeries?

Jack Zhong, Jarid Tareen, Kimberly Ashayeri, Carlos Leon, Eaman Balouch, Nicholas O'Malley, Carolyn Stickley, Constance Maglaras, Brooke O'Connell, Ethan Ayres, Charla Fischer, Yong Kim, Themistocles Protopsaltis and Aaron J. Buckland

Int J Spine Surg published online 3 April 2024
<http://ijssurgery.com/content/early/2024/04/03/8590>

This information is current as of May 2, 2024.

Email Alerts Receive free email-alerts when new articles cite this article. Sign up at:
<http://ijssurgery.com/alerts>

Does Bone Morphogenetic Protein Use Reduce Pseudarthrosis Rates in Single-Level Transforaminal Lumbar Interbody Fusion Surgeries?

JACK ZHONG, MD¹; JARID TAREEN, MD¹; KIMBERLY ASHAYERI, MD¹;
CARLOS LEON, ME¹; EAMAN BALOUCH, MD, PhD¹; NICHOLAS O'MALLEY, BS¹; CAROLYN STICKLEY, BS¹;
CONSTANCE MAGLARAS, PhD; BROOKE O'CONNELL, MS¹; ETHAN AYRES, MD¹; CHARLA FISCHER, MD¹;
YONG KIM, MD¹; THEMISTOCLES PROTOPSALTIS, MD, FAAOS¹; AND AARON J. BUCKLAND, MBBS, FRACS^{1,2,3}

¹Department of Orthopedics, Division of Spine, NYU Langone Health, New York, NY, USA; ²Melbourne Orthopedic Group, Melbourne, Australia; ³Spine and Scoliosis Research Associates Australia, Windsor, Australia

ABSTRACT

Background: Recombinant human bone morphogenetic protein 2 (rhBMP-2, or BMP for short) is a popular biological product used in spine surgeries to promote fusion and avoid the morbidity associated with iliac crest autograft. BMP's effect on pseudarthrosis in transforaminal lumbar interbody fusion (TLIF) remains unknown.

Objective: To assess the rates of pseudarthrosis in single-level TLIF with and without concurrent use of BMP.

Methods: This was a retrospective cohort study conducted at a single academic institution. Adults undergoing primary single-level TLIF with a minimum of 1 year of clinical and radiographic follow-up were included. BMP use was determined by operative notes at index surgery. Non-BMP cases with iliac crest bone graft were excluded. Pseudarthrosis was determined using radiographic and clinical evaluation. Bivariate differences between groups were assessed by independent *t* test and χ^2 analyses, and perioperative characteristics were analyzed by multiple logistic regression.

Results: One hundred forty-eight single-level TLIF patients were included. The mean age was 59.3 years, and 52.0% were women. There were no demographic differences between patients who received BMP and those who did not. Pseudarthrosis rates in patients treated with BMP were 6.2% vs 7.5% in the no BMP group ($P = 0.756$). There was no difference in reoperation for pseudarthrosis between patients who received BMP (3.7%) vs those who did not receive BMP (7.5%, $P = 0.314$). Patients who underwent revision surgery for pseudarthrosis more commonly had diabetes with end-organ damage (revised 37.5% vs not revised 1.4%, $P < 0.001$). Multiple logistic regression analysis demonstrated no reduction in reoperation for pseudarthrosis related to BMP use (OR 0.2, 95% CI 0.1–3.7, $P = 0.269$). Diabetes with end-organ damage (OR 112.6, 95% CI 5.7–2225.8, $P = 0.002$) increased the risk of reoperation for pseudarthrosis.

Conclusions: BMP use did not reduce the rate of pseudarthrosis or the number of reoperations for pseudarthrosis in single-level TLIFs. Diabetes with end-organ damage was a significant risk factor for pseudarthrosis.

Clinical Relevance: BMP is frequently used “off-label” in transforaminal lumbar interbody fusion; however, little data exists to demonstrate its safety and efficacy in this procedure.

Level of Evidence: 3.

Biologics

Keywords: transforaminal interbody fusion, TLIF, bone morphogenetic protein, BMP, pseudarthrosis, fusion, diabetes mellitus, single-level, complications

KEY POINTS

1. A total of 148 single-level adult TLIFs with a minimum of 1-year follow-up were included to compare the effects of BMP on rates of pseudarthrosis.
2. There was no difference in rates of pseudarthrosis or revision for pseudarthrosis among TLIFs with and without BMP use.
3. Diabetes with end-organ damage was shown to be a significant risk factor for pseudarthrosis on multivariate logistic regression.

INTRODUCTION

Degenerative lumbar spine disease is a common cause of back pain. Transforaminal lumbar interbody fusion (TLIF) is a commonly performed procedure to treat degenerative lumbar diseases,¹ including severe degenerative disc disease, spondylolisthesis, postlaminectomy instability, pseudarthrosis, and trauma, among others.² The procedure involves the removal of degenerated disc material, placement of bone graft and an interbody device in the disc space, and posterior instrumentation to provide initial stability and aid in fusion.³

The placement of the interbody device improves sagittal alignment, restores disc and foraminal height, and provides indirect decompression of foraminal and canal stenosis.⁴ TLIF increases surface area for fusion, which enhances fusion rates.^{4,5}

Pseudarthrosis is a failure of bone fusion after attempted spinal arthrodesis such as in TLIF,⁶ usually at a minimum of 6 months after surgery.⁷ Pseudarthrosis occurs in 3% to 22% of single-level TLIF patients,⁸⁻¹⁰ and revision for pseudarthrosis occurs in 8% of patients with single- or double-level TLIF.¹¹ Surgical technique, instrumentation type, biologics, nutrition, smoking, past medical history, revision surgery, radiographic parameters, and medications have all been identified as influencing the rate of fusion after spine surgery.^{6,12-14} Pseudarthrosis commonly presents with symptoms of new pain or neurological change, but about 22% can be asymptomatic.¹⁵ Pseudarthrosis accounts for 45% to 56% of all revisions, and it remains a common problem after spinal fusion.¹⁶ Pseudarthrosis is also associated with a significantly higher cost for patients.¹⁷

Recombinant human bone morphogenetic protein-2 (rhBMP-2, or BMP for short; Infuse, Medtronic, Minneapolis, MN, USA, and Sofamor Danek, Memphis, TN, USA) is a transforming growth factor- β used to induce bone formation in spine fusion.¹⁸ Only a select few of more than 20 BMPs have been shown to have properties related to fusion.¹⁹ BMP has been used in orthopedic fusions as in maxillofacial reconstruction.^{17,19} BMP is approved by the Food and Drug Administration for anterior lumbar interbody fusions, but surgeons commonly use it off-label in open and minimally invasive (MIS) TLIF as an adjunct for allograft and autograft bone with hopes of increasing fusion rates.^{20,21} BMP has a higher fusion rate than iliac crest bone graft (ICBG) in posterior lumbar fusion and anterior lumbar interbody fusion, but BMP's role in TLIF remains controversial.^{20,21}

The purpose of the present study was to investigate whether BMP use reduces the rate of pseudarthrosis in single-level TLIF and to identify other factors associated with pseudarthrosis.

METHODS

Inclusion and Exclusion Criteria

This is a retrospective analysis at a single high-volume tertiary care center in the United States of adult patients undergoing primary single-level TLIF for degenerative pathologies with a minimum of 1-year follow-up. Adult patients undergoing MIS/hybrid single-level TLIF with a minimum of 1-year follow-up were

included. Patients were excluded if they were younger than 18 years, had less than 1 year of clinical follow-up, underwent open TLIF procedure, underwent ICBG use without BMP, or had a history of prior fusion, infection, trauma, or malignancy. Patients with prior microdiscectomy and laminectomy were not excluded.

Data Source

All orthopedic and neurosurgical spine patients undergoing primary single-level TLIF surgery from 2012 to 2019 were included in the analysis. Data were collected by manual review of electronic medical records for demographics, intraoperative variables, surgical outcomes, and 90-day perioperative outcomes. Demographics include age, medical comorbidities, Charlson Comorbidity Index, American Society of Anesthesiologists classification, and tobacco use. Intraoperative variables included surgical technique, graft choice, interbody cage, blood loss, and length of stay. When possible, the volumes of BMP and cancellous allograft were recorded.

Complications for single-level TLIF patients were reviewed from the time of surgery until their last follow-up date. Medical complication was defined as cardiac, pulmonary, urinary, or any other nonsurgical complications. Wound complications were defined as superficial or deep infection and wound dehiscence. Motor neurological complications included weakness on physical examination and cauda equina syndrome. Other neurological complications tracked were radiculitis, sensory deficit, and persistent pain. Reoperation and the reason for reoperation were reviewed from the operation reports until the final clinical follow-up. Development of pseudarthrosis and revision for pseudarthrosis were tracked until final clinical follow-up. Patients were classified as having pseudarthrosis in our study if they had a minimum of 6 months of postoperative⁷ radiographic evidence of progressive radiolucent lines around implants, with incomplete graft integration on radiographs or computed tomography images. Patients who underwent revision for pseudarthrosis all had intraoperative evidence of pseudarthrosis noted in their surgical note by incomplete bridging bone and persistent motion at the index surgical level.

Surgical Technique

MIS-TLIF was performed via dual lumbar posterior paramedian or Wiltse incision of approximately 2 to 3 cm using a muscle-sparing approach and limited exposure of the facet capsule and lamina. Interbody fusion was performed with endplate preparation in which

the intervertebral disc was removed, and the vertebral endplates were prepared to expose bleeding bone. The hybrid midline technique utilizes both the midline approach for decompression and insertion of interbody device, as well as the paramedian incisions for screw placement. This technique combines the advantages of a midline decompression while avoiding lateral dissection and minimizing soft-tissue trauma with MIS screw insertion.²² Cage placement was performed after placing allograft and autograft (\pm BMP) anterior and contralateral to the cage to provide graft and BMP containment. All TLIF procedures were performed with bilateral pedicle screw placement. Depending on surgeon preference, pedicle screws were placed either before or after interbody implantation.

Statistical Analysis

Statistical analysis was conducted to compare patients who had reoperation for pseudarthrosis and those who did not in terms of BMP use, demographics, and surgical factors. Independent sample *t* test was used to compare quantitative variables, and χ^2 test was used for categorical variables. Multiple logistic regression was used to find the odds ratios for predictors of reoperation for pseudarthrosis. Kaplan-Meier survival curve and Mantel-Cox test were used to determine the difference in survivorship to reoperation. SPSS software was used for statistical analysis (IBM, Armonk, New York). Statistical significance was set at $P < 0.05$.

RESULTS

Demographics

There were 148 primary single-level TLIFs: 81 (54.7%) with BMP use and 67 (45.3%) with no BMP use. No differences in demographics or medical comorbidities were found between patients who received BMP and those who did not (Table 1). The mean age was

59.3 years, and 52.0% were women. Smoking status was similar between BMP and non-BMP groups (BMP 40.7% vs non-BMP 38.8%, $P = 0.811$). Mean body mass index was 29.2 and was not different between groups (BMP 30.0 vs non-BMP 28.2, $P = 0.125$). Charlson Comorbidity Index (BMP 2.2 vs non-BMP 2.8, $P = 0.113$) and American Society of Anesthesiologist (BMP 2.3 vs non-BMP 2.3, $P = 0.818$) were similar. There were similar proportions of patients who were diabetic (BMP 12.3% vs non-BMP 16.4% $P = 0.480$) or had chronic obstructive pulmonary disease (COPD) (BMP 6.2% vs non-BMP 7.5%, $P = 0.756$). BMP patients had longer average follow-up (BMP 790.4 vs non-BMP 560.3 days, $P < 0.001$).

Surgical Outcomes

Patients who received BMP had lower estimated blood loss (EBL; Table 2; BMP 169.6 ± 133.2 vs non-BMP 257.3 ± 206.6 mL, $P = 0.002$). The average volume of BMP used was 1.5 mL, and cancellous allograft used was on average 32.1 mL in non-BMP cases and 38.0 mL in BMP cases ($P = 0.182$). BMP cases were more likely to have local autograft ($P = 0.001$), ICBG ($P = 0.014$), and cellular bone allograft ($P < 0.001$). BMP patients received expandable interbody cages more often (77.8% vs 34.4%, $P < 0.001$). There were no differences in other operative characteristics between BMP and non-BMP groups.

Complications

Postoperative complication rates at 90 days were 14.8% in the BMP group and 22.4% in the non-BMP group (Table 3, $P = 0.235$). There was no difference in wound complications, medical complications, or neurological complications in the perioperative 90-day period until the last follow-up. Of the neurological complications, the most common was new or recurrent

Table 1. Comparison of demographics among single-level TLIFs with and without BMP use.

Demographics	No BMP	BMP	Total	<i>P</i>
<i>N</i>	67 (45.3%)	81 (54.7%)	148	
Age, y	60.4 \pm 11.7	58.5 \pm 12.0	59.3 \pm 11.9	0.339
Female gender	39 (56.7%)	39 (48.1%)	77 (52.0%)	0.299
Body mass index	28.2 \pm 5.7	30.0 \pm 8.3	29.2 \pm 7.3	0.125
Current/past smoker	26 (38.8%)	33 (40.7%)	59 (39.9%)	0.811
Charlson Comorbidity Index	2.8 \pm 2.5	2.2 \pm 1.5	2.5 \pm 2.1	0.113
Diabetes mellitus	11 (16.4%)	10 (12.3%)	21 (14.2%)	0.480
Diabetes with end-organ damage	3 (4.5%)	2 (2.5%)	5 (3.4%)	0.501
History of chronic obstructive pulmonary disease	5 (7.5%)	5 (6.2%)	10 (6.8%)	0.756
American Society of Anesthesiologists classification	2.3 \pm 0.7	2.3 \pm 0.6	2.3 \pm 0.6	0.818
Days of follow-up	560.3 \pm 275.4	790.4 \pm 440.2	686.2 \pm 390.8	<0.001

Abbreviations: BMP, recombinant human bone morphogenetic protein 2; TLIF, transforaminal lumbar interbody fusion.

Note: Data presented as *n* (%) or mean \pm SD.

Table 2. Comparison of surgical outcomes among single-level TLIFs with and without BMP use.

Surgical Outcomes	No BMP	BMP	Total	P
Operative time, min	219.1 ± 60.2	220.6 ± 70.7	219.9 ± 65.9	0.894
Estimated blood loss, mL	257.3 ± 206.6	169.6 ± 133.2	209.0 ± 175.0	0.002
Fluoroscopic dosage, mGy	54.6 ± 42.2	54.9 ± 57.1	54.8 ± 51.6	0.973
Tranexamic acid, mL	1746.7 ± 1074.2	2152.2 ± 979.5	1922.4 ± 1037.0	0.297
Intraoperative complications	4 (6.0%)	4 (4.9%)	8 (5.4%)	0.782
Durotomy	2 (3.0%)	2 (2.5%)	4 (2.7%)	0.847
Neuromonitoring changes	2 (3.0%)	2 (2.5%)	4 (2.7%)	0.847
BMP volume, mL	0 ± 0	1.5 ± 0.4	1.5 ± 0.4	<0.001
Cancellous allograft use	6 (9.0%)	6 (7.4%)	12 (8.1%)	0.731
Cancellous allograft volume, mL	32.1 ± 8.2	38.0 ± 18.7	36.8 ± 17.2	0.182
Local autograft use	46 (68.7%)	73 (90.1%)	119 (80.4%)	0.001
Iliac crest bone graft use	0 (0.0%)	7 (8.6%)	7 (4.7%)	0.014
Deminerzalized bone matrix use	6 (9.0%)	6 (7.4%)	12 (8.1%)	0.731
Bone marrow aspirate use	8 (11.9%)	16 (29.8%)	24 (16.2%)	0.199
Cellular bone allograft	35 (52.2%)	4 (4.9%)	39 (26.4%)	<0.001
Expandable cage use	33 (34.4%)	63 (77.8%)	96 (64.9%)	<0.001
Length of stay, d	3.5 ± 3.1	3.0 ± 2.1	3.2 ± 2.6	0.219

Abbreviations: BMP, recombinant human bone morphogenetic protein 2; TLIF, transforaminal lumbar interbody fusion.

Note: Data presented as n (%) or mean ± SD.

radiculopathy, which occurred in 9.9% in BMP vs 19.4% in non-BMP ($P = 0.098$). Of those, 23.8% of radiculopathy (BMP 25.0% vs non-BMP 23.1%, $P = 0.920$) resolved without surgical intervention.

Return to Operating Room

BMP use did not affect pseudarthrosis diagnosed at a minimum of 1-year follow-up (Table 3, BMP 6.2% vs no BMP 7.5%, $P = 0.756$). The majority (4.1%) of pseudarthrosis occurred in the 1- to 2-year postoperative period. Of the 10 total patients who showed clinical evidence of pseudarthrosis, 8 needed reoperation and 2 were treated nonoperatively (Table 4). BMP use did not reduce reoperation for pseudarthrosis (BMP 3.7% vs no

BMP 7.5%, $P = 0.314$), did not alter the time to reoperation ($P = 0.877$, Figure), and did not affect revision rates at any time point until the last follow-up. The revision rate at follow-up was 11.1% for BMP and 17.9% for non-BMP patients ($P = 0.238$). Reasons for reoperation did not differ between the BMP and non-BMP groups. A total of 12.8% of patients underwent reoperations involving the same level, while 6.1% had reoperations at an adjacent level. A total of 6.1% of patients had revision for adjacent segments stenosis, while 5.4% had revisions for central or foraminal stenosis.

Patients who underwent revision for pseudarthrosis tended to be younger (Table 5, revised 55.1 ± 12.9 vs not revised 59.6 ± 11.8 years old, $P = 0.304$), had diabetes

Table 3. Comparison of perioperative complications among single-level TLIFs with and without BMP use.

Postoperative Complications	No BMP	BMP	Total	P
Postoperative complications 0–90 d	15 (22.4%)	12 (14.8%)	27 (18.2%)	0.235
Wound complications 0–90 d	1 (1.5%)	0 (0.0%)	1 (0.7%)	0.270
Medical complications 0–90 d	5 (7.5%)	4 (4.9%)	9 (6.1%)	0.522
Neurological complication 0–90 d	3 (4.5%)	5 (6.2%)	8 (5.4%)	0.650
Complications at 90-d Follow-Up				
Any readmission to follow-up	11 (16.4%)	8 (9.9%)	19 (12.8%)	0.236
All postoperative complications or readmission to follow-up	29 (43.3%)	26 (32.1%)	55 (37.2%)	0.161
Any neurological complications postoperative follow-up	20 (29.9%)	17 (21.0%)	37 (25.0%)	0.215
Motor weakness	2 (3.0%)	1 (1.2%)	3 (2.0%)	0.452
Stenosis	0 (0.0%)	1 (1.2%)	1 (0.7%)	0.361
Radiculopathy	13 (19.4%)	8 (9.9%)	21 (14.2%)	0.098
Radiculopathy resolved spontaneously without surgery	3 (23.1%)	2 (25.0%)	5 (23.8%)	0.920
Sensory deficit	2 (3.0%)	3 (3.7%)	5 (3.4%)	0.810
Persistent pain	4 (6.0%)	3 (3.7%)	7 (4.7%)	0.518
Pseudarthrosis at a minimum of 1-y follow-up	5 (7.5%)	5 (6.2%)	10 (6.8%)	0.756
0–1 y	1 (1.5%)	2 (2.5%)	3 (2.0%)	0.549
1–2 y	4 (6.0%)	2 (2.5%)	6 (4.1%)	
2+ y	0 (0.0%)	1 (1.2%)	1 (0.7%)	
Medical complications, postoperative to follow-up	5 (7.5%)	4 (4.9%)	9 (6.1%)	0.522
Wound complications, postoperative to follow-up	2 (3.0%)	1 (1.2%)	3 (2.0%)	0.452

Abbreviations: BMP, recombinant human bone morphogenetic protein 2; TLIF, transforaminal lumbar interbody fusion.

Note: Data presented as n (%).

Table 4. Comparison of reoperations among single-level TLIFs with and without BMP use.

Reoperation	No BMP	BMP	Total	P
Return to OR 30 d	2 (3.0%)	3 (3.7%)	5 (3.4%)	0.810
Return to OR 90 d	3 (4.5%)	3 (3.7%)	6 (4.1%)	0.812
Return to OR to follow-up	12 (17.9%)	9 (11.1%)	21 (14.2%)	0.238
Levels Involved				
Reoperation at the same level as index surgery	11 (16.4%)	9 (9.9%)	19 (12.8%)	0.236
Reoperation at the adjacent level of index surgery	5 (7.5%)	4 (4.9%)	9 (6.1%)	0.522
Reason for reoperation				
Any neurological symptom	10 (14.9%)	8 (9.9%)	18 (12.2%)	0.350
Pseudarthrosis	5 (7.5%)	3 (3.7%)	8 (5.4%)	0.314
Adjacent segment stenosis	5 (7.5%)	4 (4.9%)	9 (6.1%)	0.522
Central or foraminal stenosis	3 (4.5%)	5 (6.2%)	8 (5.4%)	0.65
Wound infection/complication	0 (0.0%)	1 (1.2%)	1 (0.7%)	0.361
Instrumentation (migration/prominence/failure)	0 (0.0%)	1 (1.2%)	1 (0.7%)	0.361
Hematoma/seroma	0 (0.0%)	1 (1.2%)	1 (0.7%)	0.361
Days to revision surgery	400.3 ± 260.4	394.6 ± 297.0	398.0 ± 267.9	0.965

Abbreviations: BMP, recombinant human bone morphogenetic protein 2; OR, operating room; TLIF, transforaminal lumbar interbody fusion.
 Note: Reoperations and reason for reoperation were recorded by clinical and operative notes at the study institution.

with end-organ damage (revised 37.5% vs not revised 1.4%, $P < 0.001$), and had a history of COPD (revised 25.0% vs not revised 5.7%, $P = 0.035$). Clinical diagnosis of pseudarthrosis occurred 1 to 2 years after index surgery in 60.0% (6/10) of patients later revised for pseudarthrosis. Time to reoperation for pseudarthrosis was on average 536.3 days after index surgery, though that was not significantly different from time to revision for other reasons (305.8 days, $P = 0.057$).

Multiple logistic regression analysis demonstrated that diabetes mellitus with end-organ damage (Table 6; OR 122.6, $P = 0.001$) was the strongest risk factor for later revision for pseudarthrosis. BMP use was not protective (OR = 0.2, $P = 0.269$), nor was the use of an expandable cage (OR 2.6, $P = 0.412$). History of COPD, smoking, and bone marrow aspirate use also did not affect the risk of reoperation for pseudarthrosis.




Figure. Kaplan-Meier survivorship curve for days to reoperation between patients who received recombinant human bone morphogenetic protein 2 (BMP) and those who did not in the index surgery. Abbreviation: Cum, cumulative.

Table 5. Comparison of single-level transforaminal lumbar interbody fusions that underwent reoperation for pseudarthrosis vs those that did not.

Variable	No Pseudarthrosis Reoperation	Reoperation for Pseudarthrosis	Total	P
<i>N</i>	140 (94.6%)	8 (5.4%)	148	
Demographic Characteristics				
Age, y	59.6 ± 11.8	55.1 ± 12.9	59.3 ± 11.9	0.304
18–29	0 (0%)	0 (0%)	0 (0%)	0.876
30–41	10 (7.1%)	1 (9.1%)	11 (7.4%)	
42–53	34 (24.3%)	2 (25.0%)	36 (24.3%)	
54–65	44 (31.4%)	3 (37.5%)	47 (31.8%)	
≥66	52 (37.1%)	2 (25.0%)	54 (36.5%)	
Female Gender	74 (52.9%)	3 (37.5%)	77 (52.0%)	0.398
BMI	29.0 ± 7.2	32.7 ± 8.5	39.2 ± 7.3	0.155
Current/past smoker	55 (39.3%)	4 (50.0%)	59 (39.9%)	0.547
Charlson Comorbidity Index	2.4 ± 2.1	2.9 ± 2.2	2.4 ± 2.1	0.565
Diabetes mellitus	18 (12.9%)	3 (37.5%)	21 (14.2%)	0.052
Diabetes with end-organ damage	2 (1.4%)	3 (37.5%)	5 (3.5%)	<0.001
History of COPD	8 (5.7%)	2 (25.0%)	10 (6.8%)	0.035
American Society of Anesthesiologist classification	2.2 ± 0.6	2.5 ± 0.9	2.3 ± 0.6	0.298
Days of follow-up	679.3 ± 295.1	806.9 ± 299.9	686.2 ± 390.8	0.371
Index Surgery Operative Characteristics				
Operative time, min	218.1 ± 63.5	251.8 ± 98.7	219.9 ± 65.9	0.160
Estimated blood loss, mL	208.0 ± 178.8	225.0 ± 92.6	208.9 ± 175.0	0.791
Fluoroscopic dosage, mGy	50.8 ± 45.8	110.5 ± 91.2	54.8 ± 51.6	0.003
BMP use	78 (55.7%)	3 (37.5%)	81 (54.7%)	0.314
Average BMP volume, mL	1.5 ± 0.4	1.4 ± 0.0	1.5 ± 0.4	0.565
Cancellous allograft use	98 (70.0%)	5 (62.5%)	103 (69.3%)	0.654
Cancellous allograft volume, mL	37.1 ± 17.6	33.0 ± 6.7	36.8 ± 17.2	0.612
Local autograft use	113 (80.7%)	6 (75.0%)	119 (80.4%)	0.692
Iliac crest bone graft use	6 (4.3%)	1 (12.5%)	8 (4.7%)	0.287
Deminerzalized bone matrix use	12 (8.6%)	0 (0.0%)	12 (8.1%)	0.388
Tranexamic acid, mL	1776.9 ± 961.4	3240.2 ± 827.0	1922.4 ± 1037.0	0.017
Bone marrow aspirate use	22 (15.7%)	2 (25.0%)	24 (16.2%)	0.488
Cellular bone allograft	37 (26.4%)	2 (25.0%)	39 (26.4%)	0.929
Expandable cage use	90 (64.3%)	6 (75.0%)	96 (64.9%)	0.537
Length of stay, d	3.2 ± 2.7	4.3 ± 1.8	3.2 ± 2.6	0.261
Pseudarthrosis at a minimum of 1 y follow-up	2 (1.4%)	8 (80%)	10 (6.8%)	< 0.001
0–1 y	1 (0.75%)	2 (25.0%)	3 (2.0%)	< 0.001
1–2 y	1 (0.7%)	5 (62.5%)	6 (4.1%)	
2+ y	0 (0.0%)	1 (12.5%)	1 (0.7%)	
Days to revision surgery	305.8 ± 279.3	536.3 ± 189.1	398.0 ± 267.9	0.057
Neurological Symptoms After Index Surgery				
Motor deficit	2 (1.4%)	1 (12.5%)	3 (2.0%)	0.031
Stenosis	1 (0.7%)	0 (0.0%)	0 (0.0%)	0.810
Radiculopathy	19 (13.6%)	2 (25.0%)	21 (14.2%)	0.368
Radiculopathy resolved spontaneously without surgery	5 (26.3%)	0 (0.0%)	5 (23.8%)	0.406
Sensory deficit	3 (2.1%)	2 (25.0%)	5 (3.4%)	<0.001
Persistent pain	7 (5.0%)	0 (0.0%)	7 (4.7%)	0.517

Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary disease; TLIF, transforaminal lumbar interbody fusion.

Note: Data presented as *n* (%) or mean ± SD.

DISCUSSION

This retrospective study demonstrated no significant benefit from the use of BMP in single-level TLIF on developing complications or clinically significant pseudarthrosis. Chang et al reviewed the use of BMP with allograft or autograft in posterior MIS interbody fusions, showing a fusion rate of 65% to 100%, which was statistically similar to ICBG alone, autograft plus allograft, and bone marrow aspirate.²³ Overley et al also found no difference in radiographic fusion and rate of revision surgery with BMP use in single-level MIS-TLIF.²⁴ In our data, the fusion rate was 93.6% with

BMP and 92.5% without BMP, which corresponds well to the prior findings of 3% to 22% pseudarthrosis after single-level TLIF.^{8–10} However, Nandyala et al showed BMP to achieve superior arthrodesis (92%) compared with silicate-substituted calcium phosphate (65%) in single-level MIS-TLIF.²⁵

Singh et al reported a 6.8% revision rate for pseudarthrosis and 8.6% total revision rate in 610 single-to double-level MIS-TLIF with a minimum of 1-year follow-up.²⁶ This rate is slightly higher than the 5.4% revision for pseudarthrosis and lower than the 14.2% total revision rate in our study at a similar follow-up

Table 6. Multiple logistic regression analysis of outcome variables given use of BMP.

Variable	OR (95 % CI)	P
BMP use	0.2 (0.01–3.7)	0.269
Age 18–41 y (ref: age >41 y)	0.6 (0.03–15.2)	0.782
Smoking history	2.2 (0.3–18.1)	0.461
History of COPD	7.8 (0.4–147.5)	0.170
Diabetes with end-organ damage	112.6 (5.7–2225.8)	0.002
Bone marrow aspirate use	1.1 (0.1–15.9)	0.918
Local autograft use	0.3 (0.02–4.1)	0.346
Iliac crest bone graft use	21.9 (0.7–694.5)	0.080
Cellular bone allograft use	0.4 (0.02–7.3)	0.534
Expandable cage use	2.6 (0.3–25.5)	0.412
ASA classification>3 (ref: ≤3)	0.6 (0.001–391.0)	0.874

Abbreviations: ASA, American Society of Anesthesiologists; BMP, recombinant human bone morphogenetic protein 2; COPD, chronic obstructive pulmonary disease; ref, reference.

Note: Values in boldface represent statistical significance at $P < 0.05$. Nagelkerke $R^2 = 0.381$. Hosmer Lemeshow test $P = 0.731$.

time. The use of bilateral pedicle screw fixation in our study and unilateral pedicle screw fixation in Singh et al may account for this difference.²⁶ In Singh et al, patients undergoing revision for pseudarthrosis were significantly younger and had higher rates of smoking trending toward significance ($P = 0.054$).²⁶ These data support our findings; additionally, we demonstrated that diabetes mellitus with end-organ damage was an independent risk factor. Smoking did not affect the rate of pseudarthrosis or BMP use in our study. Emami et al also failed to show smoking to be a risk factor for pseudarthrosis after MIS-TLIF.⁶

Technical differences in arthrodesis and pedicle screw could indeed account for pseudarthrosis rates. Gologorsky et al demonstrated higher rates of pseudarthrosis in TLIF using unilateral pedicle screw fixation compared with bilateral screw fixation.²⁷ Bilateral pedicle screw fixation was standard in the current study. This helps explain why the revision rate for pseudarthrosis is lower in the current study compared with the results from unilateral screw fixation in Singh et al.²⁸ The expandable cage was also identified to possibly affect pseudarthrosis rates, but the results of the bivariate and multivariate analysis did not show an increased risk of pseudarthrosis requiring revision from use of expandable interbody cage. Hawasli et al reported similarly in a study of MIS-TLIF that use of an expandable cage did not increase the risk of pseudarthrosis.²⁹

Poorly controlled diabetes with end-organ damage was a risk factor for revision for pseudarthrosis. Glassman et al found significantly higher rates of nonunion in diabetics after lumbar spine surgery, but no difference was found in fusion rates between insulin-dependent and noninsulin-dependent diabetics.³⁰ Contrarily, Bendo et al reported that diabetic patients did not show worse

outcomes after posterior lumbar fusions.³¹ Takahashi et al noted pseudarthrosis rates of 20% in diabetes vs 3% in nondiabetics ($P = 0.095$) after lumbar surgery.³² Freedman et al noted no difference in infection or nonunion rates in diabetic patients with spondylolisthesis in the Spine Patients Outcomes Research Trial.³³

With no consensus for radiographic criteria for diagnosis of pseudarthrosis, most diagnoses are made clinically with correlation with multiple imaging modalities.³⁴ Computed tomography can show subsidence or lucency around the fusion construct, and plain radiographs provide evidence of deficient fusion mass morphology. Surgical exploration remains the gold standard of diagnosis, but it is rarely performed due to morbidity.³⁴ Most pseudarthrosis patients in our study (8/10) underwent revision and had intraoperative evidence of incomplete bony integration and movement at the fused segment, confirming pseudarthrosis.

It is unclear why some pseudarthroses remain asymptomatic. Prior data have shown that younger age and noninstrumented fusions increased the likelihood of symptomatic pseudarthrosis.^{35,36} All patients in Singh et al who presented with radiographically confirmed pseudarthrosis were symptomatic and needed revision arthrodesis.²⁶ Pseudarthrosis revision surgery was reported to cost \$20,267.²⁶ Emami et al identified revision surgery to be a risk factor for pseudarthrosis (8%) in MIS-TLIF patients at a minimum of 1-year follow-up.¹¹ Patient satisfaction and symptoms are also related to psychosocial factors.^{37–39}

Chun et al conducted a meta-analysis of pseudarthrosis in lumbar fusions and found that BMP-2 has a higher fusion rate (94%) compared with autograft (89%) and demineralized bone matrix (89%).^{37,40} Surgical techniques reviewed⁴⁰ were single-level^{41,42} and multi-level⁴³ posterolateral lumbar arthrodesis with pedicle screw and rods using BMP vs ICBG. BMP group had significantly lower EBL in our study, in which open TLIF procedures were excluded entirely. Several studies found higher use of BMP^{44,45} and lower blood loss in MIS-TLIF compared with open TLIF.^{45–47} Hey et al attributed differences in EBL to intraoperative factors and not BMP use.⁴⁸

Given the absence of protection against reoperation, pseudarthrosis, or complications, BMP use was not demonstrated by the authors as a cost-effective strategy in single-level TLIF. Glassman et al reported an average cost of \$4,764.90 for BMP use in 1- to 4-level lumbar fusions.³⁰ Furthermore, BMP has been associated with clinical side effects including inflammatory complications such as cervical spine swelling and seromas,

postoperative radiculitis, ectopic bone formation, vertebral bone resorption, subsidence, retrograde ejaculation, bladder retention, hematoma, wound dehiscence, and infection.⁴⁹ Singh et al reported 1.7% revision for heterotopic ossification and osteolysis after small kit (4.2 mg) and large kit (12 mg) BMP use in index MIS-TLIF.²⁶ Hegelson et al reported a 41% osteolysis rate at 1 to 2 years with 6 mg of BMP use in TLIF.⁵⁰ Mindea et al report 11.4% radicular symptoms not attributable to structural etiologies with 4.2 mg BMP used per level.⁵¹ In our data, BMP use did not increase perioperative or postoperative complications. Postoperative radiculitis rate was 14.2% with or without BMP use. Hofstetter et al showed a positive correlation between dosage of BMP used and complications in a meta-analysis of spinal arthrodesis.⁵² Small (4.2 mg or 2.8 mL) and extra small (2.1 mg or 1.4 mL) dosages used in our study may result in no discernable increase in complication rates with BMP.

Limitations

The retrospective design limits this study's ability to randomize patients and determine causation. This study results are from a high-volume single center and may not be applicable to a smaller, low-volume center. It is difficult to control for technique differences among surgeons, and BMP application to contralateral posterior elements and disc space was not analyzed. The definition of clinical pseudarthrosis as a surgeon depends on documentation with radiographic correlation of pseudarthrosis. Not all patients noted to have pseudarthrosis were revised. Although the volume of some grafts such as BMP and cancellous allograft was routinely included, the documentation of the amounts of other grafts used (demineralized bone matrix, bone marrow aspirate, local autograft, etc) was noted to be inaccurate and inconsistent. Therefore, those graft variables were analyzed as binomial variables instead of characterizing volumetric differences. Biological use is subject to surgeon preference, and selection bias may exist for which the patient receives BMP or other grafts. BMP is often used in conjunction with other biologics and grafts, which may confound the relationship between BMP and pseudarthrosis. Furthermore, surgeon techniques for pedicle screw placement, rod materials, and arthrodesis techniques could all affect pseudarthrosis rates but were out of the scope of the analysis in the current article. Surgeon preference and contractual obligations to certain cage types and brands could not be adequately accounted for, but this does represent real

practice environments where such factors can influence implant choice.

CONCLUSION

BMP did not reduce pseudarthrosis and associated reoperations in single-level TLIF or affect rates of postoperative complications. Patients with a history of diabetes with end-organ damage are at higher risk of needing reoperation for pseudarthrosis after single-level TLIF.

REFERENCES

1. Uçar BY, Özcan Ç, Polat Ö, Aman T. Transforaminal lumbar Interbody fusion for lumbar degenerative disease: patient selection and perspectives. *Orthop Res Rev.* 2019;11:183–189. doi:10.2147/ORR.S204297
2. Garg B, Mehta N. Minimally invasive transforaminal lumbar interbody fusion (MI-TLIF): a review of indications, technique, results and complications. *J Clin Orthop Trauma.* 2019;10(Suppl 1):S156–S162. doi:10.1016/j.jcot.2019.01.008
3. Mobbs RJ, Phan K, Malham G, Seex K, Rao PJ. Lumbar interbody fusion: techniques, indications and comparison of interbody fusion options including PLIF. *J Spine Surg.* 2015;1(1):2–18. doi:10.3978/j.issn.2414-469X.2015.10.05
4. Derman PB, Albert TJ. Interbody fusion techniques in the surgical management of degenerative lumbar spondylolisthesis. *Curr Rev Musculoskelet Med.* 2017;10(4):530–538. doi:10.1007/s12178-017-9443-2
5. Macki M, Bydon M, Weingart R, et al. Posterolateral fusion with interbody for lumbar spondylolisthesis is associated with less repeat surgery than posterolateral fusion alone. *Clin Neurol Neurosurg.* 2015;138:117–123. doi:10.1016/j.clineuro.2015.08.014
6. Emami A, Faloon M, Sahai N, et al. Risk factors for pseudarthrosis in minimally-invasive transforaminal lumbar interbody fusion. *Asian Spine J.* 2018;12(5):830–838. doi:10.31616/asj.2018.12.5.830
7. Rager O, Schaller K, Payer M, Tchernin D, Ratib O, Tessitore E. SPECT/CT in differentiation of pseudarthrosis from other causes of back pain in lumbar spinal fusion: report on 10 consecutive cases. *Clin Nucl Med.* 2012;37(4):339–343. doi:10.1097/RLU.0b013e318239248b
8. Challier V, Boissiere L, Obeid I, et al. One-level lumbar degenerative spondylolisthesis and posterior approach: is transforaminal lateral Interbody fusion mandatory? A randomized controlled trial with 2-year follow-up. *Spine (Phila Pa 1976).* 2017;42(8):531–539. doi:10.1097/BRS.0000000000001857
9. Rihn JA, Patel R, Makda J, et al. Complications associated with single-level transforaminal lumbar interbody fusion. *Spine J.* 2009;9(8):623–629. doi:10.1016/j.spinee.2009.04.004
10. Overley SC, McAnany SJ, Anwar MA, et al. Predictive factors and rates of fusion in minimally invasive transforaminal lumbar interbody fusion utilizing rhBMP-2 or mesenchymal stem cells. *Int J Spine Surg.* 2019;13(1):46–52. doi:10.14444/6007
11. Emami A, Faloon M, Sahai N, et al. Risk factors for pseudarthrosis in minimally-invasive transforaminal lumbar interbody fusion. *Asian Spine J.* 2018;12(5):830–838. doi:10.31616/asj.2018.12.5.830

12. Adogwa O, Buchowski JM, Lenke LG, et al. Comparison of rod fracture rates in long spinal deformity constructs after transforaminal versus anterior lumbar interbody fusions: a single-institution analysis. *J Neurosurg Spine*. 2019;32(1):1–8. doi:10.3171/2019.7.SPINE19630
13. Jenkins NW, Parrish JM, Mayo BC, et al. The identification of risk factors for increased postoperative pain following minimally invasive transforaminal lumbar interbody fusion. *Eur Spine J*. 2020;29(6):1304–1310. doi:10.1007/s00586-020-06344-4
14. Teton ZE, Cheaney B, Obayashi JT, Than KD. PEEK Interbody devices for multilevel anterior cervical discectomy and fusion: association with more than 6-fold higher rates of pseudarthrosis compared to structural allograft. *J Neurosurg Spine*. 2020;1–7. doi:10.3171/2019.11.SPINE19788
15. Jung J-M, Chung CK, Kim CH, Yang SH, Ko YS. Prognosis of symptomatic pseudarthrosis observed at 1 year after lateral lumbar interbody fusion. *Spine (Phila Pa 1976)*. 2021;46(18):E1006–E1013. doi:10.1097/BRS.0000000000003980
16. Leven D, Cho SK. Pseudarthrosis of the cervical spine: risk factors, diagnosis and management. *Asian Spine J*. 2016;10(4):776–786. doi:10.4184/asj.2016.10.4.776
17. Jain A, Yeramaneni S, Kebaish KM, et al. Cost-utility analysis of rhBMP-2 use in adult spinal deformity surgery. *Spine (Phila Pa 1976)*. 2020;45(14):1009–1015. doi:10.1097/BRS.0000000000003442
18. Cohen LL, Yang BW, O'Neill NP, Proctor MR, Glotzbecker MP, Hedequist DJ. Use of recombinant human bone morphogenetic protein for revision cervical spine fusion in children with down syndrome: a case series. *J Neurosurg Pediatr*. 2020;1–5. doi:10.3171/2019.11.PEDS19622
19. Herford AS. The use of recombinant human bone morphogenetic protein-2 (rhBMP-2) in maxillofacial trauma. *Chin J Traumatol*. 2017;20(1):1–3. doi:10.1016/j.cjtee.2016.05.004
20. Oliveira O de, Martins SPR, Lima W de, Gomes MM. The use of bone morphogenetic proteins (BMP) and pseudarthrosis, a literature review. *Rev Bras Ortop*. 2017;52(2):124–140. doi:10.1016/j.rboe.2016.03.005
21. Vaz K, Verma K, Protosaltis T, Schwab F, Lonner B, Errico T. Bone grafting options for lumbar spine surgery: a review examining clinical efficacy and complications. *SAS J*. 2010;4(3):75–86. doi:10.1016/j.esas.2010.01.004
22. Reinshagen C, Ruess D, Walcott BP, Molcanyi M, Goldbrunner R, Rieger B. A novel minimally invasive technique for lumbar decompression, realignment, and navigated interbody fusion. *J Clin Neurosci*. 2015;22(9):1484–1490. doi:10.1016/j.jocn.2015.03.019
23. Chang KY, Hsu WK. Spinal biologics in minimally invasive lumbar surgery. *Minim Invasive Surg*. 2018;2018:5230350. doi:10.1155/2018/5230350
24. Overley SC, McAnany SJ, Anwar MA, et al. Predictive factors and rates of fusion in minimally invasive transforaminal lumbar interbody fusion utilizing rhBMP-2 or mesenchymal stem cells. *Int J Spine Surg*. 2019;13(1):46–52. doi:10.14444/6007
25. Nandyala SV, Marquez-Lara A, Fineberg SJ, Pelton M, Singh K. Controlled trial of silicate-substituted calcium phosphate versus rhBMP-2 in a minimally invasive transforaminal lumbar interbody fusion. *Spine (Phila Pa 1976)*. 2014;39(3):185–191. doi:10.1097/BRS.000000000000106
26. Singh K, Nandyala SV, Marquez-Lara A, et al. Clinical sequelae after rhBMP-2 use in a minimally invasive transforaminal lumbar interbody fusion. *Spine J*. 2013;13(9):1118–1125. doi:10.1016/j.spinee.2013.07.028
27. Gologorsky Y, Skovrlj B, Steinberger J, et al. Increased incidence of pseudarthrosis after unilateral instrumented transforaminal lumbar interbody fusion in patients with lumbar spondylosis: clinical article. *J Neurosurg Spine*. 2014;21(4):601–607. doi:10.3171/2014.6.SPINE13488
28. Singh K, Nandyala SV, Marquez-Lara A, et al. Clinical sequelae after rhBMP-2 use in a minimally invasive transforaminal lumbar interbody fusion. *Spine J*. 2013;13(9):1118–1125. doi:10.1016/j.spinee.2013.07.028
29. Hawasli AH, Khalifeh JM, Chatrath A, Yarbrough CK, Ray WZ. Minimally invasive transforaminal lumbar interbody fusion with expandable versus static interbody devices: radiographic assessment of sagittal segmental and pelvic parameters. *Neurosurg Focus*. 2017;43(2):E10. doi:10.3171/2017.5.FOCUS17197
30. Glassman SD, Carreon LY, Campbell MJ, et al. The perioperative cost of infuse bone graft in posterolateral lumbar spine fusion. *Spine J*. 2008;8(3):443–448. doi:10.1016/j.spinee.2007.03.004
31. Bendo JA, Spivak J, Moskovich R, Neuwirth M. Instrumented posterior arthrodesis of the lumbar spine in patients with diabetes mellitus. *Am J Orthop (Belle Mead NJ)*. 2000;29(8):617–620.
32. Takahashi S, Suzuki A, Toyoda H, et al. Characteristics of diabetes associated with poor improvements in clinical outcomes after lumbar spine surgery. *Spine (Phila Pa 1976)*. 2013;38(6):516–522. doi:10.1097/BRS.0b013e318273583a
33. Freedman MK, Hilibrand AS, Blood EA, et al. The impact of diabetes on the outcomes of surgical and nonsurgical treatment of patients in the spine patient outcomes research trial. *Spine (Phila Pa 1976)*. 2011;36(4):290–307. doi:10.1097/BRS.0b013e3181ef9d8c
34. Peters MJM, Bastiaenen CHG, Brans BT, Weijers RE, Willems PC. The diagnostic accuracy of imaging modalities to detect pseudarthrosis after spinal fusion—a systematic review and meta-analysis of the literature. *Skeletal Radiol*. 2019;48(10):1499–1510. doi:10.1007/s00256-019-03181-5
35. Phillips FM, Carlson G, Emery SE, Bohlman HH. Anterior cervical pseudarthrosis. *Spine*. 1997;22(14):1585–1589. doi:10.1097/00007632-199707150-00012
36. Raizman NM, O'Brien JR, Poehling-Monaghan KL, Yu WD. Pseudarthrosis of the spine. *J Am Acad Orthop Surg*. 2009;17(8):494–503. doi:10.5435/00124635-200908000-00003
37. Chun DS, Baker KC, Hsu WK. Lumbar pseudarthrosis: a review of current diagnosis and treatment. *Neurosurg Focus*. 2015;39(4):E10. doi:10.3171/2015.7.FOCUS15292
38. Carpenter CT, Dietz JW, Leung KY, Hanscom DA, Wagner TA. Repair of a pseudarthrosis of the lumbar spine. A functional outcome study. *J Bone Joint Surg Am*. 1996;78(5):712–720. doi:10.2106/00004623-199605000-00011
39. Adogwa O, Verla T, Thompson P, et al. Affective disorders influence clinical outcomes after revision lumbar surgery in elderly patients with symptomatic adjacent-segment disease, recurrent stenosis, or pseudarthrosis: clinical article. *J Neurosurg Spine*. 2014;21(2):153–159. doi:10.3171/2014.4.SPINE12668
40. Hsu WK, Nickoli MS, Wang JC, et al. Improving the clinical evidence of bone graft substitute technology in lumbar spine surgery. *Global Spine J*. 2012;2(4):239–248. doi:10.1055/s-0032-1315454
41. Dawson E, Bae HW, Burkus JK, Stambough JL, Glassman SD. Recombinant human bone morphogenetic protein-2 on an absorbable collagen sponge with an osteoconductive bulking agent in posterolateral arthrodesis with instrumentation: a prospective

randomized trial. *J Bone Joint Surg Am.* 2009;91(7):1604–1613. doi:10.2106/JBJS.G.01157

42. Boden SD, Kang J, Sandhu H, Heller JG. Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: a prospective, randomized clinical pilot trial 2002 Volvo award in clinical studies. *Spine (Phila Pa 1976).* 2002;27(23):2662–2673. doi:10.1097/00007632-200212010-00005

43. Glassman SD, Carreon L, Djurasovic M, et al. Posterolateral lumbar spine fusion with INFUSE bone graft. *Spine J.* 2007;7(1):44–49. doi:10.1016/j.spinee.2006.06.381

44. Wu RH, Fraser JF, Härtl R. Minimal access versus open transforaminal lumbar interbody fusion: meta-analysis of fusion rates. *Spine (Phila Pa 1976).* 2010;35(26):2273–2281. doi:10.1097/BRS.0b013e3181cd42cc

45. Price JP, Dawson JM, Schwender JD, Schellhas KP. Clinical and radiologic comparison of minimally invasive surgery with traditional open transforaminal lumbar interbody fusion: a review of 452 patients from a single center. *Clin Spine Surg.* 2018;31(2):E121–E126. doi:10.1097/BSD.0000000000000581

46. Hockley A, Ge D, Vasquez-Montes D, et al. Minimally invasive versus open transforaminal lumbar interbody fusion surgery: an analysis of opioids, nonopioid analgesics, and perioperative characteristics. *Global Spine J.* 2019;9(6):624–629. doi:10.1177/2192568218822320

47. Ge DH, Stekas ND, Varlotta CG, et al. Comparative analysis of two transforaminal lumbar interbody fusion techniques: open TLIF: versus: wiltse MIS TLIF. *Spine (Phila Pa 1976).* 2019;44(9):E555–E560. doi:10.1097/BRS.0000000000002903

48. Hey HWD, Hee HT. Open and minimally invasive transforaminal lumbar interbody fusion: comparison of intermediate results and complications. *Asian Spine J.* 2015;9(2):185–193. doi:10.4184/asj.2015.9.2.185

49. James AW, LaChaud G, Shen J, et al. A review of the clinical side effects of bone morphogenetic protein-2. *Tissue Eng Part B Rev.* 2016;22(4):284–297. doi:10.1089/ten.TEB.2015.0357

50. Helgeson MD, Lehman RA, Patzkowski JC, Dmitriev AE, Rosner MK, Mack AW. Adjacent vertebral body osteolysis with bone morphogenetic protein use in transforaminal lumbar interbody fusion. *Spine J.* 2011;11(6):507–510. doi:10.1016/j.spinee.2011.01.017

51. Mindea SA, Shih P, Song JK. Recombinant human bone morphogenetic protein-2-induced radiculitis in elective minimally invasive transforaminal lumbar interbody fusions: a series review. *Spine (Phila Pa 1976).* 2009;34(14):1480–1484. doi:10.1097/BRS.0b013e3181a396a1

52. Hofstetter CP, Hofer AS, Levi AD. Exploratory meta-analysis on dose-related efficacy and morbidity of bone morphogenetic protein in spinal arthrodesis surgery. *J Neurosurg Spine.* 2016;24(3):457–475. doi:10.3171/2015.4.SPINE141086

Funding: The authors received no financial support for the research, authorship, and/or publication of this article.

Declaration of Conflicting Interests:

A.J.B. is a paid consultant for Nuvasive, K2M-Stryker, Medtronic, Altus Spine, Evolution Spine, and EOS Imaging. Additionally, he reports contracts/grants from Nuvasive (paid to institution); royalties/licenses from Nuvasive, Evolution Spine, and Altus Spine; support for attending meetings/travel from Nuvasive and Medtronic; serving as director and chair of the Spine and Scoliosis Research Associates Australia (nonprofit); and received fellowship support from Nuvasive paid to the institution. T.S.P. is a paid consultant for Globus Medical, Innovaxis, K2M-Stryker, Medicea International, and Nuvasive and owns stocks/stock options with Torus Medical. C.R.F. is a presenter or speaker for Expert Connect; a paid consultant for Stryker and Nuvasive; has received payment/honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Amplify; and has received payment for expert testimony from the departments of Justice in the southern and eastern districts of New York. Y.H.K. receives IP royalties and is a paid consultant of Biomet. The remaining authors have no disclosures.

Corresponding Author: Aaron J. Buckland, Melbourne Orthopaedic Group, 33 The Ave, Windsor, Vic 3181, Melbourne, Australia; aaron.buckland@spineand scoliosis.org

This manuscript is generously published free of charge by ISASS, the International Society for the Advancement of Spine Surgery. Copyright © 2024 ISASS. To see more or order reprints or permissions, see <http://ijssurgery.com>.